Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a flavivirus through the bite of an infected mosquito. Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure L1655. Interestingly, Yellow fever got its name from the characteristic yellowing of the skin and eyes that occurs from the development of jaundice when the virus attacks the liver. Although there is supportive treatment available for managing Yellow Fever, there are currently no antivirals developed to specifically treat Yellow Fever. Vaccination with Yellow Fever vaccine is therefore considered to be the most important and effective measure to protect against Yellow Fever, with protective immunity developing within 10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days FDA Label. The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease" L1654.
Yellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America L1653. The World Health Organization recommends routine vaccination in countries where Yellow Fever is endemic, and for travellers going to endemic areas as proof of vaccination is often a requirement at border crossings to prevent international spread of the disease L1653, L1657.
Yellow Fever Vaccine is a subcutaneously administered vaccination for the active immunization and prophylaxis of yellow fever in pediatric patients 9 months of age and older. It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection FDA Label, A32118. The FDA recommends vaccination with Yellow Fever Vaccine for persons living in or travelling to endemic areas and for laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Flunisolide | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Flunisolide. |
| Betamethasone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Betamethasone. |
| Triamcinolone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Triamcinolone. |
| Prednisone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Prednisone. |
| Fludrocortisone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Fludrocortisone. |
| Hydrocortisone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Hydrocortisone. |
| Prednisolone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Prednisolone. |
| Methylprednisolone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Methylprednisolone. |
| Trilostane | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Trilostane. |
| Budesonide | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Budesonide. |
| Dexamethasone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Dexamethasone. |
| Corticotropin | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Corticotropin. |
| Cortisone acetate | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cortisone acetate. |
| Paramethasone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Paramethasone. |
| Aldosterone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Aldosterone. |
| Fluprednisolone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Fluprednisolone. |
| Meprednisone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Meprednisone. |
| Melengestrol | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Melengestrol. |
| Deflazacort | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Deflazacort. |
| Cortivazol | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cortivazol. |
| Prednylidene | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Prednylidene. |
| Cloprednol | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cloprednol. |
| Cortisone | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cortisone. |
| Etanercept | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Etanercept. |
| Peginterferon alfa-2a | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Peginterferon alfa-2a. |
| Interferon alfa-n1 | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon alfa-n1. |
| Interferon alfa-n3 | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon alfa-n3. |
| Peginterferon alfa-2b | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Peginterferon alfa-2b. |
| Anakinra | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Anakinra. |
| Interferon gamma-1b | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon gamma-1b. |
| Interferon alfa-2a | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon alfa-2a. |
| Aldesleukin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Aldesleukin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Yellow fever vaccine. |
| Gemtuzumab ozogamicin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Gemtuzumab ozogamicin. |
| Pegaspargase | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pegaspargase. |
| Infliximab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Infliximab. |
| Interferon beta-1b | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon beta-1b. |
| Interferon alfacon-1 | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon alfacon-1. |
| Trastuzumab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Trastuzumab. |
| Rituximab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Rituximab. |
| Basiliximab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Basiliximab. |
| Muromonab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Muromonab. |
| Ibritumomab tiuxetan | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Alemtuzumab. |
| Cyclosporine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cyclosporine. |
| Alefacept | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Alefacept. |
| Efalizumab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Interferon alfa-2b. |
| Natalizumab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Natalizumab. |
| Daclizumab | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Daclizumab. |
| Phenylalanine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Phenylalanine. |
| Bortezomib | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Bortezomib. |
| Cladribine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cladribine. |
| Carmustine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Carmustine. |
| Amsacrine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Amsacrine. |
| Bleomycin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Bleomycin. |
| Chlorambucil | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Raltitrexed. |
| Mitomycin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Mitomycin. |
| Bexarotene | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Bexarotene. |
| Vindesine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Vindesine. |
| Floxuridine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Floxuridine. |
| Indomethacin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Indomethacin. |
| Tioguanine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Tioguanine. |
| Vinorelbine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Dexrazoxane. |
| Sorafenib | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Sorafenib. |
| Streptozocin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Streptozocin. |
| Trifluridine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Trifluridine. |
| Gemcitabine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Gemcitabine. |
| Teniposide | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Teniposide. |
| Epirubicin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Lenalidomide. |
| Altretamine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Altretamine. |
| Zidovudine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Zidovudine. |
| Cisplatin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Vincristine. |
| Fluorouracil | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pentostatin. |
| Methotrexate | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Methotrexate. |
| Carbamazepine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Carbamazepine. |
| Vinblastine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Vinblastine. |
| Linezolid | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Linezolid. |
| Imatinib | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Imatinib. |
| Clofarabine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Clofarabine. |
| Pemetrexed | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Pemetrexed. |
| Mycophenolate mofetil | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Daunorubicin. |
| Irinotecan | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Irinotecan. |
| Methimazole | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Methimazole. |
| Etoposide | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Etoposide. |
| Sulfasalazine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Dacarbazine. |
| Temozolomide | The risk or severity of infection can be increased when Yellow fever vaccine is combined with Temozolomide. |